Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Virgil Brown

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Disorders

Concepts & Ideas

Risk Factors

Anatomy

Liver

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
34
Ginsberg, Henry
13
Le, Ngoc-Anh
6
Greten, Heiner
5
Li, X
5
Raines, Jeffrey
5
Herrington, David
4
Kwiterovich, Peter
4
Goldberg, Ira
4
Davis, Warren
4
Davis, Warren
4
Oka, Kazuhiro
3
Willens, Howard
3
Cahill, Edward
3
Innis-Whitehouse, W
3
Knopp, Robert

Sign-in to see all Coauthors

Publications

TOP 3
Brown W Virgil; Fujioka Ken; Wilson Peter W F; Woodworth Kristina A
Obesity: why be concerned?
Brown W Virgil
Microvascular complications of diabetes mellitus: renal protection accompanies cardiovascular protection.
Brown William Virgil
Safety of statins.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Virgil Brown (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Brown W Virgil; Fujioka Ken; Wilson Peter W F; Woodworth Kristina A
Obesity: why be concerned?
The American journal of medicine 2009;122(4 Suppl 1):S4-11.
2008: Brown W Virgil
Microvascular complications of diabetes mellitus: renal protection accompanies cardiovascular protection.
The American journal of cardiology 2008;102(12A):10L-13L.
2008: Brown William Virgil
Safety of statins.
Current opinion in lipidology 2008;19(6):558-62.
2008: Fruchart Jean-Charles; Sacks Frank; Hermans Michel P; Assmann Gerd; Brown W Virgil; Ceska Richard; Chapman M John; Dodson Paul M; Fioretto Paola; Ginsberg Henry N; Kadowaki Takashi; Lablanche Jean-Marc; Marx Nikolaus; Plutzky Jorge; Reiner Zeljko; Rosenson Robert S; Staels Bart; Stock Jane K; Sy Rody; Wanner Christoph; Zambon Alberto; Zimmet Paul
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia.
The American journal of cardiology 2008;102(10 Suppl):1K-34K.
2008: Fruchart Jean-Charles; Sacks Frank M; Hermans Michel P; Assmann Gerd; Brown W Virgil; Ceska Richard; Chapman M John; Dodson Paul M; Fioretto Paola; Ginsberg Henry N; Kadowaki Takashi; Lablanche Jean-Marc; Marx Nikolaus; Plutzky Jorge; Reiner Zeljko; Rosenson Robert S; Staels Bart; Stock Jane K; Sy Rody; Wanner Christoph; Zambon Alberto; Zimmet Paul;
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient.
Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease 2008;5(4):319-35.
2008: Garelnabi Mahdi O; Brown W Virgil; Le Ngoc-Anh
Evaluation of a novel colorimetric assay for free oxygen radicals as marker of oxidative stress.
Clinical biochemistry 2008;41(14-15):1250-4.
2008: Harrison David G; Brown W Virgil; Raggi Paolo
Enhanced hype.
The American journal of cardiology 2008;102(3):368-9.
2007: Brown W Virgil
Expert commentary: the safety of fibrates in lipid-lowering therapy.
The American journal of cardiology 2007;99(6A):19C-21C.
2006: Brown W Virgil
Different definitions of the metabolic syndrome and risk for recurrent cardiovascular disease.
Nature clinical practice. Endocrinology & metabolism 2006;2(9):492-3.
2006: Rimland David; Guest Jodie L; Hernández-Ramos Isabel; Del Rio Carlos; Le N Anh; Brown W Virgil
Antiretroviral therapy in HIV-positive women is associated with increased apolipoproteins and total cholesterol.
Journal of acquired immune deficiency syndromes (1999) 2006;42(3):307-13.
2005: Rimland D; Guest J L; Hernández I; Del Rio C; Le N A; Brown W V
Antiretroviral therapy in HIV-positive men is associated with increased apolipoprotein CIII in triglyceride-rich lipoproteins.
HIV medicine 2005;6(5):326-33.
2005: Willens Howard J; Chirinos Julio A; Brown W Virgil; Davis Warren W; Herrington David M; Mosca Lori; Homma Shunichi; Moussa Mohamad; Walker Gail; Raines Jeffrey K
Usefulness of arterial compliance in the thigh in predicting exercise capacity in individuals without coronary heart disease.
The American journal of cardiology 2005;96(2):306-10.
2005: Le Ngoc-Anh; Brown W Virgil; Davis Warren W; Herrington David M; Mosca Lori; Homma Shunichi; Eggleston Barry; Willens Howard J; Raines Jeffrey K
Comparison of the relation of triglyceride-rich lipoproteins and muscular artery compliance in healthy women versus healthy men.
The American journal of cardiology 2005;95(9):1049-54.
2005: Klein Richard L; McHenry M Brent; Lok Kerry H; Hunter Steven J; Le Ngoc-Anh; Jenkins Alicia J; Zheng Deyi; Semler Andrea; Page Grier; Brown W Virgil; Lyons Timothy J; Garvey W Timothy;
Apolipoprotein C-III protein concentrations and gene polymorphisms in Type 1 diabetes: associations with microvascular disease complications in the DCCT/EDIC cohort.
Journal of diabetes and its complications 2005;19(1):18-25.
2004: Saliashvili Gocha; Davis Warren W; Harris Matthey T; Le Ngoc-Anh; Brown W Virgil
Simvastatin improved arterial compliance in high-risk patients.
Vascular and endovascular surgery 2004;38(6):519-23.
2004: McKenney James M; Brown W Virgil; Cohen Jerome D; Cahill Edward
The National Lipid Association surveys of consumers, physicians, and pharmacists regarding an over-the-counter statin in the United States: is this a good idea?
The American journal of cardiology 2004;94(9A):16F-21F.
2004: Pasternak Richard C; McKenney James M; Brown W Virgil; Cahill Edward; Cohen Jerome D
Understanding physician and consumer attitudes concerning cholesterol management: results from the National Lipid Association surveys.
The American journal of cardiology 2004;94(9A):9F-15F.
2004: Klein Richard L; McHenry M Brent; Lok Kerry H; Hunter Steven J; Le Ngoc-Anh; Jenkins Alicia J; Zheng Deyi; Semler Andrea J; Brown W Virgil; Lyons Timothy J; Garvey W Timothy;
Apolipoprotein C-III protein concentrations and gene polymorphisms in type 1 diabetes: associations with lipoprotein subclasses.
Metabolism: clinical and experimental 2004;53(10):1296-304.
2004: Rifai Nader; Cooper Gerald R; Brown W Virgil; Friedewald William; Havel Richard J; Myers Gary L; Warnick G Russell
Clinical Chemistry journal has contributed to progress in lipid and lipoprotein testing for fifty years.
Clinical chemistry 2004;50(10):1861-70.
2004: McKenney James M; Bradberry J Chris; Talbert Robert L; Cahill Edward; Brown W Virgil
National survey of pharmacists about coronary heart disease, hypercholesterolemia, nonprescription statintherapy, and pharmacists' services.
Journal of the American Pharmacists Association : JAPhA 2004;44(5):562-8.
2004: Herrington David M; Brown W Virgil; Mosca Lori; Davis Warren; Eggleston Barry; Hundley W Gregory; Raines Jeffrey
Relationship between arterial stiffness and subclinical aortic atherosclerosis.
Circulation 2004;110(4):432-7.
2004: Gradek W Quinten; Harris Matthey T; Yahia Najat; Davis Warren W; Le Ngoc-Anh; Brown W Virgil
Polyunsaturated fatty acids acutely suppress antibodies to malondialdehyde-modified lipoproteins in patients with vascular disease.
The American journal of cardiology 2004;93(7):881-5.
2004: Brown William Virgil
Metabolic syndrome and risk of stroke.
Clinical cornerstone 2004;6 Suppl 3():S30-4.
2003: Brown William Virgil; Moussa Mohamad
Perspectives from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial--Lipid Lowering Trial and the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm.
Current opinion in lipidology 2003;14(6):593-7.
2003: Breyer Emelita D; Howard Sarah; Raje Neeta; Allison Stuart; Apkarian Robert; Brown W Virgil; Strasters Joost K
Study of lipid and apolipoprotein binding interactions using vesicle affinity capillary electrophoresis.
Analytical chemistry 2003;75(19):5160-9.
2003: Herrington David M; Kesler Karen; Reiber J h C; Davis Warren; Brown W Virgil; Helms Ronald; Mallon Stephen M; Raines Jeffrey
Arterial compliance adds to conventional risk factors for prediction of angiographic coronary artery disease.
American heart journal 2003;146(4):662-7.
2003: Brown William Virgil; Davis Warren; Harris Matthey
Implications of the heart protection study for reducing coronary events in high-risk patients.
Current atherosclerosis reports 2003;5(5):358-63.
2003: Brown W Virgil
Cholesterol absorption inhibitors: defining new options in lipid management.
Clinical cardiology 2003;26(6):259-64.
2003: Willens Howard J; Davis Warren; Herrington David M; Wade Karen; Kesler Karen; Mallon Steve; Brown W Virgil; Reiber J H C; Raines Jeffrey K
Relationship of peripheral arterial compliance and standard cardiovascular risk factors.
Vascular and endovascular surgery 2003;37(3):197-206.
2003: Harris Matthey; Davis Warren; Brown W Virgil
Ezetimibe.
Drugs of today (Barcelona, Spain : 1998) 2003;39(4):229-47.
2003: Brown W Virgil
Benefits of statin therapy in patients with special risks: coronary bypass surgery, stable coronary disease, and acute coronary syndromes.
Clinical cardiology 2003;26(4 Suppl 3):III13-8.
2003: Brown W Virgil
Reaching goal: conquering the treatment gaps in dyslipidemia management.
Clinical cardiology 2003;26(4 Suppl 3):III1-2.
2003: Blasetto James W; Stein Evan A; Brown W Virgil; Chitra Rohini; Raza Ali
Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.
The American journal of cardiology 2003;91(5A):3C-10C; discussion 10C.
2003: Sprecher Dennis L; Watkins Timothy R; Behar Solomon; Brown W Virgil; Rubins Hanna B; Schaefer Ernst J
Importance of high-density lipoprotein cholesterol and triglyceride levels in coronary heart disease.
The American journal of cardiology 2003;91(5):575-80.
2002: Brown W Virgil; Bays Harold E; Hassman David R; McKenney James; Chitra Rohini; Hutchinson Howard; Miller Elinor;
Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial.
American heart journal 2002;144(6):1036-43.
2002: Brown W Virgil
Promising therapies for cholesterol reduction.
Managed care (Langhorne, Pa.) 2002;11(9 Suppl):10-4.
2001: Brown W V
Preventive strategies for reducing coronary heart disease-related morbidity and mortality in patients with multiple risk factors.
The Journal of the American Osteopathic Association 2001;101(9 Suppl):S6-11.
2001: Brown W V
What are the priorities for managing cholesterol effectively?
The American journal of cardiology 2001;88(4A):21F-4F.
2001: Brown W V
Therapies on the horizon for cholesterol reduction.
Clinical cardiology 2001;24(8 Suppl):III24-7.
2001: Brown W V
Statin therapy in the new millennium: is there room for improvement?
Clinical cardiology 2001;24(8 Suppl):III1-2.
2001: Brown W V
New therapies on the horizon.
The American journal of managed care 2001;7(5 Suppl):S148-51.
2001: Brown W V
Novel approaches to lipid lowering: what is on the horizon?
The American journal of cardiology 2001;87(5A):23B-27B.
2000: Brown W V
Risk factors for vascular disease in patients with diabetes.
Diabetes, obesity & metabolism 2000;2 Suppl 2():S11-8.
2000: Le N A; Li X; Kyung S; Brown W V
Evidence for the in vivo generation of oxidatively modified epitopes in patients with atherosclerotic endothelium.
Metabolism: clinical and experimental 2000;49(10):1271-7.
2000: Brown W V
The benefit of aggressive lipid lowering.
Atherosclerosis. Supplements 2000;1(1):15-9.
2000: Brown W V
Cholesterol lowering in atherosclerosis.
The American journal of cardiology 2000;86(4B):29H-32H.
2000: Anderson J W; Davidson M H; Blonde L; Brown W V; Howard W J; Ginsberg H; Allgood L D; Weingand K W
Long-term cholesterol-lowering effects of psyllium as an adjunct to diet therapy in the treatment of hypercholesterolemia.
The American journal of clinical nutrition 2000;71(6):1433-8.
2000: Le N A; Innis-Whitehouse W; Li X; Bakker-Arkema R; Black D; Brown W V
Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin.
Metabolism: clinical and experimental 2000;49(2):167-77.
1999: Breyer E D; Le N A; Li X; Martinson D; Brown W V
Apolipoprotein C-III displacement of apolipoprotein E from VLDL: effect of particle size.
Journal of lipid research 1999;40(10):1875-82.
1999: Pitt B; Waters D; Brown W V; van Boven A J; Schwartz L; Title L M; Eisenberg D; Shurzinske L; McCormick L S
Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.
The New England journal of medicine 1999;341(2):70-6.
1998: Schwartz J S; Brown W V; Hlatky M; Castelli W
Cardiovascular disease and lipoproteins: available evidence and remaining questions. Reactor panel and open forum.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 1998;1(2):125-30.
1998: Brown W V
Landmark trials in lipid reduction.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 1998;1(2):110-4.
1998: Innis-Whitehouse W; Li X; Brown W V; Le N A
An efficient chromatographic system for lipoprotein fractionation using whole plasma.
Journal of lipid research 1998;39(3):679-90.
1998: Brown W V
Impact of dyslipidaemia. Lessons from clinical trials.
PharmacoEconomics 1998;14 Suppl 3():1-9.
1997: Li X; Innis-Whitehouse W; Brown W V; Le N A
Protocol for the preparation of a segmental linear polyacrylamide gradient gel: simultaneous determination of Lp[a], LDL, and HDL particle sizes.
Journal of lipid research 1997;38(12):2603-14.
1997: McCormick L S; Black D M; Waters D; Brown W V; Pitt B
Rationale, design, and baseline characteristics of a trial comparing aggressive lipid lowering with Atorvastatin Versus Revascularization Treatments (AVERT).
The American journal of cardiology 1997;80(9):1130-3.
1997: Frank E; Rothenberg R; Brown W V; Maibach H
Basic demographic and professional characteristics of US women physicians.
The Western journal of medicine 1997;166(3):179-84.
1997: Brown W V
Hypercholesterolemia in the United States: how far have we come?
The American journal of medicine 1997;102(2A):3-6.
1997: Brown W V
Epidemiology and treatment of hypercholesterolemia: where we are today. Introduction.
The American journal of medicine 1997;102(2A):1-2.
1996: Weintraub W S; Wenger N K; Parthasarathy S; Brown W V
Hyperlipidemia versus iron overload and coronary artery disease: yet more arguments on the cholesterol debate.
Journal of clinical epidemiology 1996;49(12):1353-8.
1996: Bakker-Arkema R G; Davidson M H; Goldstein R J; Davignon J; Isaacsohn J L; Weiss S R; Keilson L M; Brown W V; Miller V T; Shurzinske L J; Black D M
Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.
JAMA : the journal of the American Medical Association 1996;275(2):128-33.
1995: Brown W V
Niacin for lipid disorders. Indications, effectiveness, and safety.
Postgraduate medicine 1995;98(2):185-9, 192-3.
1994: Brown W V
Hydroxymethylglutaryl coenzyme a reductase inhibition: fluvastatin, a clinical investigators' update. Introduction.
The American journal of cardiology 1994;73(14):1D-2D.
1994: Brown W V
Lipoprotein disorders in diabetes mellitus.
The Medical clinics of North America 1994;78(1):143-61.
1993: Stamler J; Stamler R; Brown W V; Gotto A M; Greenland P; Grundy S; Hegsted D M; Luepker R V; Neaton J D; Steinberg D
Serum cholesterol. Doing the right thing.
Circulation 1993;88(4 Pt 1):1954-60.
1993: Pearson T A; Brown W V; Donato K; Franklin F A; Luepker R B; McBride P E; Mullis R M; Scott L W; Shannon B; Shekelle R B
Lipids. Workshop IV. AHA Prevention Conference III. Behavior change and compliance: keys to improving cardiovascular health.
Circulation 1993;88(3):1397-401.
1992: Brown W V
When do we treat hypercholesterolemia?
Clinical cardiology 1992;15(11 Suppl 3):III10-4; discussion III 15-7.
1992: Brown W V
When do we treat hypercholesterolemia?
Clinical cardiology 1992;15(11):III10-4; discussion III15-7.
1992: Brown W V; Breslow J L
Genetic lipoprotein abnormalities producing high blood cholesterol.
Heart disease and stroke : a journal for primary care physicians 1992;1(6):405-7.
1992: Ishimura-Oka K; Semenkovich C F; Faustinella F; Goldberg I J; Shachter N; Smith L C; Coleman T; Hide W A; Brown W V; Oka K
A missense (Asp250----Asn) mutation in the lipoprotein lipase gene in two unrelated families with familial lipoprotein lipase deficiency.
Journal of lipid research 1992;33(5):745-54.
1992: Brown W V
President's address to the 64th scientific sessions of the American Heart Association.
Circulation 1992;85(5):1969-71.
1992: Brown W V
Lipoproteins: what, when, and how often to measure.
Heart disease and stroke : a journal for primary care physicians 1992;1(1):20-6.
1991: Mishra L; Le N A; Brown W V; Mezey E
Effect of acute intravenous alcohol on plasma lipoproteins in man.
Metabolism: clinical and experimental 1991;40(11):1128-30.
1991: Oka K; Nakano T; Tkalcevic G T; Scow R O; Brown W V
Molecular cloning of mouse hepatic triacylglycerol lipase: gene expression in combined lipase-deficient (cld/cld) mice.
Biochimica et biophysica acta 1991;1089(1):13-20.
1990: Brown W V
Review of clinical trials: proving the lipid hypothesis.
European heart journal 1990;11 Suppl H():15-20.
1990: Hunninghake D B; Knopp R H; Schonfeld G; Goldberg A C; Brown W V; Schaefer E J; Margolis S; Dobs A S; Mellies M J; Insull W
Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study.
Atherosclerosis 1990;85(1):81-9.
1990: Brown W V
Clinical trials including an update on the Helsinki Heart Study.
The American journal of cardiology 1990;66(6):11A-15A.
1990: Oka K; Tkalcevic G T; Nakano T; Tucker H; Ishimura-Oka K; Brown W V
Structure and polymorphic map of human lipoprotein lipase gene.
Biochimica et biophysica acta 1990;1049(1):21-6.
1990: Nakano T; Tucker H; Oka K; Brown W V
A simple semi-dry capillary transfer of DNA.
BioTechniques 1990;8(2):173-4.
1990: Brown W V; Howard W J
Treatment of lipoprotein disorders.
Cardiovascular clinics 1990;20(3):157-76.
1990: Brown W V
Dietary recommendations to prevent coronary heart disease.
Annals of the New York Academy of Sciences 1990;598():376-88.
1989: Grundy S M; Brown W V; Dietschy J M; Ginsberg H; Goodnight S; Howard B; La Rosa J C; McGill H C
AHA Conference Report on Cholesterol. Basis for dietary treatment.
Circulation 1989;80(3):729-34.
1989: Oka K; Tkalcevic G T; Stocks J; Galton D J; Brown W V
Nucleotide sequence of PvuII polymorphic site at the human lipoprotein lipase gene locus.
Nucleic acids research 1989;17(16):6752.
1989: Oka K; Yuan J G; Senda M; Masibay A S; Qasba P K; Masuno H; Scow R O; Paterniti J R; Brown W V;
Expression of lipoprotein lipase gene in combined lipase deficiency.
Biochimica et biophysica acta 1989;1008(3):351-4.
1989: Oka K; Wang-Iverson P; Paterniti J R; Brown W V
Interaction of lipoprotein lipase with heparin.
Annals of the New York Academy of Sciences 1989;556():173-80.
1989: Brown W V
Review of clinical studies of fenofibrate in combination with currently approved lipid-lowering drugs.
Cardiology 1989;76 Suppl 1():45-51; discussion 52-4.
1989: Brown W V
Treatment of hypercholesterolaemia with fenofibrate: a review.
Current medical research and opinion 1989;11(5):321-30.
1988: Gibson J C; Brown W V
Effect of lipoprotein lipase and hepatic triglyceride lipase activity on the distribution of apolipoprotein E among the plasma lipoproteins.
Atherosclerosis 1988;73(1):45-55.
1988: Brown W V
The cholesterol hypothesis and the value of intervention.
The Journal of the American Osteopathic Association 1988;88(7):859-64.
1988: Brown W V
Focus on fenofibrate.
Hospital practice (Office ed.) 1988;23 Suppl 1():31-40.
1987: Brown W V
Potential use of fenofibrate and other fibric acid derivatives in the clinic.
The American journal of medicine 1987;83(5B):85-9.
1987: Brown W V
Fenofibrate, a third-generation fibric acid derivative.
The American journal of medicine 1987;83(5B):1-2.
1987: Knopp R H; Brown W V; Dujovne C A; Farquhar J W; Feldman E B; Goldberg A C; Grundy S M; Lasser N L; Mellies M J; Palmer R H
Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia.
The American journal of medicine 1987;83(5B):50-9.
1987: Smith D A; Karmally W; Brown W V
Treating hyperlipidemia, Part III: Drug therapy.
Geriatrics 1987;42(8):55-9, 62.
1987: Gibson J C; Goldberg R B; Rubinstein A; Ginsberg H N; Brown W V; Baker S; Joffe B I; Seftel H C
Plasma lipoprotein distribution of apolipoprotein E in familial hypercholesterolemia.
Arteriosclerosis (Dallas, Tex.) 1987;7(4):401-7.
1987: Smith D A; Karmally W; Brown W V
Treating hyperlipidemia, Part II: Making dietary control work in the elderly.
Geriatrics 1987;42(7):39-40, 42-3.
1987: Senda M; Oka K; Brown W V; Qasba P K; Furuichi Y
Molecular cloning and sequence of a cDNA coding for bovine lipoprotein lipase.
Proceedings of the National Academy of Sciences of the United States of America 1987;84(13):4369-73.
1987: Smith D A; Karmally W; Brown W V
Treating hyperlipidemia, Part I: Whether and when in the elderly.
Geriatrics 1987;42(6):33-6, 39-42, 44.
1987: Bloomgarden Z T; Karmally W; Metzger M J; Brothers M; Nechemias C; Bookman J; Faierman D; Ginsberg-Fellner F; Rayfield E; Brown W V
Randomized, controlled trial of diabetic patient education: improved knowledge without improved metabolic status.
Diabetes care 1987;10(3):263-72.
1986: Rubinstein A; Gibson J C; Ginsberg H N; Brown W V
In vitro metabolism of apolipoprotein E.
Biochimica et biophysica acta 1986;879(3):355-61.
1986: Goldberg I J; Le N A; Leeman B; Brown W V; Lindgren F T
Evidence for heterogeneity of low-density lipoprotein metabolism in the cynomolgus monkey.
Biochimica et biophysica acta 1986;879(2):179-85.
1986: Brown W V; Dujovne C A; Farquhar J W; Feldman E B; Grundy S M; Knopp R H; Lasser N L; Mellies M J; Palmer R H; Samuel P
Effects of fenofibrate on plasma lipids. Double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia.
Arteriosclerosis (Dallas, Tex.) 1986;6(6):670-8.
1986: Ginsberg H N; Le N A; Goldberg I J; Gibson J C; Rubinstein A; Wang-Iverson P; Norum R; Brown W V
Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.
The Journal of clinical investigation 1986;78(5):1287-95.
1986: Blanchette-Mackie E J; Wetzel M G; Chernick S S; Paterniti J R; Brown W V; Scow R O
Effect of the combined lipase deficiency mutation (cld/cld) on ultrastructure of tissues in mice. Diaphragm, heart, brown adipose tissue, lung, and liver.
Laboratory investigation; a journal of technical methods and pathology 1986;55(3):347-62.
1986: Faierman D; Bloomgarden Z T; Nechemias C; Brown W V
Electrocardiographic abnormalities in diabetes mellitus: association between T-wave changes and nephropathy.
The Mount Sinai journal of medicine, New York 1986;53(4):254-9.
1986: Ginsberg H; Rubenstein A; Brown W V
Medical complications of isotretinoin.
Clinics in dermatology 1986;4(1):183-9.
1986: Gibson J C; Rubinstein A; Ginsberg H N; Brown W V
Isolation of apolipoprotein E-containing lipoproteins by immunoaffinity chromatography.
Methods in enzymology 1986;129():186-98.
1986: Le N A; Bukberg P R; Ginsberg H N; Gibson J C; Brown W V
Direct determination of apolipoprotein C-III specific activity using immunoaffinity chromatography.
Methods in enzymology 1986;129():457-69.
1986: Le N A; Ramakrishnan R; Dell R B; Ginsberg H N; Brown W V
Kinetic analysis using specific radioactivity data.
Methods in enzymology 1986;129():384-95.
1985: Grundy S M; Arky R; Bray G A; Brown W V; Ernst N D; Kwiterovich P O; Mattson F; Weidman W H; Schonfeld G; Strong J P
Coronary risk factor statement for the American public. A statement of the nutrition committee.
Circulation 1985;72(5):1135A-1139A.
1985: Bershad S; Rubinstein A; Paterniti J R; Le N A; Poliak S C; Heller B; Ginsberg H N; Fleischmajer R; Brown W V
Changes in plasma lipids and lipoproteins during isotretinoin therapy for acne.
The New England journal of medicine 1985;313(16):981-5.
1985: Bukberg P R; Le N A; Ginsberg H N; Gibson J C; Rubinstein A; Brown W V
Evidence for non-equilibrating pools of apolipoprotein C-III in plasma lipoproteins.
Journal of lipid research 1985;26(9):1047-57.
1985: Goldberg I J; Mazlen R G; Rubenstein A; Gibson J C; Paterniti J R; Lindgren F T; Brown W V
Plasma lipoprotein abnormalities associated with acquired hepatic triglyceride lipase deficiency.
Metabolism: clinical and experimental 1985;34(9):832-5.
1985: Gibson J C; Rubinstein A; Brown W V; Ginsberg H N; Greten H; Norum R; Kayden H
Apo E-containing lipoproteins in low or high density lipoprotein deficiency.
Arteriosclerosis (Dallas, Tex.) 1985;5(4):371-80.
1985: Gibson J C; Rubinstein A; Ngai N; Ginsberg H N; Le N A; Gordon R E; Goldberg I J; Brown W V
Immunoaffinity isolation of apolipoprotein E-containing lipoproteins.
Biochimica et biophysica acta 1985;835(1):113-23.
1985: Brown W V; Karmally W
Coronary heart disease and the consumption of diets high in wheat and other grains.
The American journal of clinical nutrition 1985;41(5 Suppl):1163-71.
1985: Wang-Iverson P; Gibson J C; Brown W V
Plasma apolipoprotein secretion by human monocyte-derived macrophages.
Biochimica et biophysica acta 1985;834(2):256-62.
1985: Rubinstein A; Gibson J C; Paterniti J R; Kakis G; Little A; Ginsberg H N; Brown W V
Effect of heparin-induced lipolysis on the distribution of apolipoprotein e among lipoprotein subclasses. Studies with patients deficient in hepatic triglyceride lipase and lipoprotein lipase.
The Journal of clinical investigation 1985;75(2):710-21.
1985: Olivecrona T; Chernick S S; Bengtsson-Olivecrona G; Paterniti J R; Brown W V; Scow R O
Combined lipase deficiency (cld/cld) in mice. Demonstration that an inactive form of lipoprotein lipase is synthesized.
The Journal of biological chemistry 1985;260(4):2552-7.
1985: Wang-Iverson P; Ginsberg H N; Peteanu L A; Le N A; Brown W V
Apo E-mediated uptake and degradation of normal very low density lipoproteins by human monocyte/macrophages: a saturable pathway distinct from the LDL receptor.
Biochemical and biophysical research communications 1985;126(1):578-86.
1984: Le N A; Ginsberg H N; Brown W V
Protocol for efficient plasma sampling for low density lipoprotein turnover studies.
Journal of lipid research 1984;25(12):1387-91.
1984: Bloomgarden Z T; Ginsberg-Fellner F; Rayfield E J; Bookman J; Brown W V
Elevated hemoglobin A1c and low-density lipoprotein cholesterol levels in thiazide-treated diabetic patients.
The American journal of medicine 1984;77(5):823-7.
1984: Gibson J C; Rubinstein A; Brown W V
Precipitation of apo E-containing lipoproteins by precipitation reagents for apolipoprotein B.
Clinical chemistry 1984;30(11):1784-8.
1984: Brown W V; Ginsberg H; Karmally W
Diet and the decrease of coronary heart disease.
The American journal of cardiology 1984;54(5):27C-29C.
1984: Brown W V; Goldberg I J; Ginsberg H N
Treatment of common lipoprotein disorders.
Progress in cardiovascular diseases 1984;27(1):1-20.
1983: Bukberg P R; Le N A; Ginsberg H N; Gibson J C; Goldman L C; Brown W V
Direct measurement of apoprotein C-III specific activity in 125I-labeled very low density lipoproteins using immunoaffinity chromatography.
Journal of lipid research 1983;24(9):1251-60.
1983: Goldberg I J; Paterniti J R; Franklin B H; Ginsberg H N; Ginsberg-Fellner F; Brown W V
Transient lipoprotein lipase deficiency with hyperchylomicronemia.
The American journal of the medical sciences 1983;286(2):28-31.
1983: Paterniti J R; Brown W V; Ginsberg H N; Artzt K
Combined lipase deficiency (cld): a lethal mutation on chromosome 17 of the mouse.
Science (New York, N.Y.) 1983;221(4606):167-9.
1983: Gibson J C; Rubinstein A; Bukberg P R; Brown W V
Apolipoprotein E-enriched lipoprotein subclasses in normolipidemic subjects.
Journal of lipid research 1983;24(7):886-98.
1983: Goldberg I J; Paterniti J R; Brown W V
Measurement of lipoprotein lipase and hepatic triacylglycerol lipase in post-heparin plasma of the cynomolgus monkey.
Biochimica et biophysica acta 1983;752(1):172-7.
1983: Ginsberg H; Goldberg I J; Wang-Iverson P; Gitler E; Le N A; Gilbert H S; Brown W V
Increased catabolism of native and cyclohexanedione-modified low density lipoprotein in subjects with myeloproliferative diseases.
Arteriosclerosis (Dallas, Tex.) 1983;3(3):233-41.
1983: Goldberg I J; Le N A; Ginsberg H N; Paterniti J R; Brown W V
Metabolism of apoprotein B in cynomolgus monkey: evidence for independent production of low-density lipoprotein apoprotein B.
The American journal of physiology 1983;244(2):E196-201.
1982: Goldberg I J; Le N A; Paterniti J R; Ginsberg H N; Lindgren F T; Brown W V
Lipoprotein metabolism during acute inhibition of hepatic triglyceride lipase in the cynomolgus monkey.
The Journal of clinical investigation 1982;70(6):1184-92.
1982: Ginsberg H; Davidson N; Le N A; Gibson J; Ahrens E H; Brown W V
Marked overproduction of low density lipoprotein apolipoprotein B in a subject with heterozygous familial hypercholesterolemia. Effect of portacaval shunting.
Biochimica et biophysica acta 1982;712(2):250-7.
1982: Brown W V; Bloomgarden Z; Ginsberg H
Lipoproteins as risk factors for vascular disease in diabetes.
The Mount Sinai journal of medicine, New York 1982;49(3):176-86.
1982: Grundy S M; Bilheimer D; Blackburn H; Brown W V; Kwiterovich P O; Mattson F; Schonfeld G; Weidman W H
Rationale of the diet-heart statement of the American Heart Association. Report of Nutrition Committee.
Circulation 1982;65(4):839A-854A.
1982: Ginsberg H; Gilbert H S; Gibson J C; Le N A; Brown W V
Increased low-density-lipoprotein catabolism in myeloproliferative disorders.
Annals of internal medicine 1982;96(3):311-6.
1982: Wang-Iverson P; Ungar A; Bliumis J; Bukberg P R; Gibson J C; Brown W V
Human monocytes in culture synthesize and secrete lipoprotein lipase.
Biochemical and biophysical research communications 1982;104(3):923-8.
1982: Wang-Iverson P; Brown W V
Interaction of lipoprotein lipase with cultured endothelial cells.
Annals of the New York Academy of Sciences 1982;401():92-101.
1981: Ginsberg H; Le N A; Mays C; Gibson J; Brown W V
Lipoprotein metabolism in nonresponders to increased dietary cholesterol.
Arteriosclerosis (Dallas, Tex.) 1981;1(6):463-70.
1981: Gilbert H S; Ginsberg H; Fagerstrom R; Brown W V
Characterization of hypocholesterolemia in myeloproliferative disease. Relation to disease manifestations and activity.
The American journal of medicine 1981;71(4):595-602.
1981: Turner J D; Le N A; Brown W V
Effect of changing dietary fat saturation on low-density lipoprotein metabolism in man.
The American journal of physiology 1981;241(1):E57-63.
1981: Ginsberg H N; Le N A; Melish J; Steinberg D; Brown W V
Effect of a high carbohydrate diet on apoprotein-B catabolism in man.
Metabolism: clinical and experimental 1981;30(4):347-53.
1980: Melish J; Le N A; Ginsberg H; Steinberg D; Brown W V
Dissociation of apoprotein B and triglyceride production in very-low-density lipoproteins.
The American journal of physiology 1980;239(5):E354-62.
1980: Brown W
Structure and metabolism of plasma lipoproteins---an overview.
Nutrition and metabolism 1980;24 Suppl 1():1-2.
1979: Steinberg D; Grundy S M; Mok H Y; Turner J D; Weinstein D B; Brown W V; Albers J J
Metabolic studies in an unusual case of asymptomatic familial hypobetalipoproteinemia with hypolphalipoproteinemia and fasting chylomicronemia.
The Journal of clinical investigation 1979;64(1):292-301.
1979: Baginsky M L; Brown W V
A new method for the measurement of lipoprotein lipase in postheparin plasma using sodium dodecyl sulfate for the inactivation of hepatic triglyceride lipase.
Journal of lipid research 1979;20(4):548-56.
1979: Barrett-Connor E; Brown W V; Turner J; Austin M; Criqui M H
Heart disease risk factors and hormone use in postmenopausal women.
JAMA : the journal of the American Medical Association 1979;241(20):2167-9.
1979: Boberg J; Boberg M; Gross R; Turner J D; Augustin J; Brown W V
Hepatic triglyceride and lipoprotein lipase activities of post-heparin plasma in normals and hypertriglyceridemics.
Upsala journal of medical sciences 1979;84(3):215-27.
1978: Le N A; Melish J S; Roach B C; Ginsberg H N; Brown W V
Direct measurement of apoprotein B specific activity in 125I-labeled lipoproteins.
Journal of lipid research 1978;19(5):578-84.
1978: Augustin J; Freeze H; Tejada P; Brown W V
A comparison of molecular properties of hepatic triglyceride lipase and lipoprotein lipase from human post-heparin plasma.
The Journal of biological chemistry 1978;253(9):2912-20.
1977: Boberg J; Augustin J; Baginsky M L; Tejada P; Brown W V
Quantitative determination of hepatic and lipoprotein lipase activities from human postheparin plasma.
Journal of lipid research 1977;18(4):544-7.
1977: Baginsky M L; Brown W V
Differential characteristics of purified hepatic triglyceride lipase and lipoprotein lipase from human postheparin plasma.
Journal of lipid research 1977;18(4):423-37.
1977: Ehnholm C; Bensadoun A; Brown W V
Characterization of two triacylglycerol lipase activities in pig post-heparin plasma.
The Biochemical journal 1977;163(2):347-55.
1977: Kwiterovich P O; Farah J R; Brown W V; Bachorik P S; Baylin S B; Neill C A
The clinical, biochemical, and familial presentation of type V hyperlipoproteinemia in childhood.
Pediatrics 1977;59(4):513-25.
1977: Brown W V; Collins E B
End products and fermentation balances for lactic streptococci grown aerobically on low concentrations of glucose.
Applied and environmental microbiology 1977;33(1):38-42.
1976: Rosseneu M; Soetewey F; Middelhoff G; Peeters H; Brown W V
Studies of the lipid binding characteristics of the apolipoproteins from human high density lipoprotein. II. Calorimetry of the binding of apo AI and apo AII with phospholipids.
Biochimica et biophysica acta 1976;441(1):68-80.
1976: Middelhoff G; Rosseneu M; Peeters H; Brown W V
Study of the lipid binding characteristics of the apolipoproteins from human high density lipoprotein. I. Electron microscopic and gel filtration studies with synthetic phosphatidylcholines.
Biochimica et biophysica acta 1976;441(1):57-67.
1976: Baginsky M L; Brown W V
Effects of monoolein on hydrolysis of triglyceride by lipoprotein lipase in the presence of an inhibitory apolipoprotein.
Physiological chemistry and physics 1976;8(3):197-206.
1975: Ehnholm C; Shaw W; Greten H; Brown W V
Purification from human plasma of a heparin-released lipase with activity against triglyceride and phospholipids.
The Journal of biological chemistry 1975;250(17):6756-61.
1974: Wetmore S; Mahley R W; Brown W V; Schachter H
Incorporation of sialic acid into sialidase-treated apolipoprotein of human, very low density lipoprotein by a pork liver sialytransferase.
Canadian journal of biochemistry 1974;52(8):654-64.
1974: Cottrill C; Glueck C J; Leuba V; Millett F; Puppione D; Brown W V
Familial homozygous hypobetalipoproteinemia.
Metabolism: clinical and experimental 1974;23(8):779-91.
1974: Ehnholm C; Greten H; Brown W V
A comparative study of post-heparin lipolytic activity and a purified human plasma triacylglycerol lipase.
Biochimica et biophysica acta 1974;360(1):68-77.
1974: Sniderman A D; Chandler J G; Steinberg D; Brown W V
Evidence for the hepatic origin of a canine post-heparin plasma triglyceride lipase.
FEBS letters 1974;42(2):157-60.
1974: Bensadoun A; Ehnholm C; Steinberg D; Brown W V
Purification and characterization of lipoprotein lipase from pig adipose tissue.
The Journal of biological chemistry 1974;249(7):2220-7.
1974: Brown W V; Baginsky M L
Some functional aspects of apolipoproteins: apoLp-Ala inhibition of lipoprotein lipase and deinhibition by monoolein.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 1974;Suppl 4():11-6.
1973: Levy R I; Fredrickson D S; Stone N J; Bilheimer D W; Brown W V; Glueck C J; Gotto A M; Herbert P N; Kwiterovich P O; Langer T; LaRosa J; Lux S E; Rider A K; Shulman R S; Sloan H R
Cholestyramine in type II hyperlipoproteinemia. A double-blind trial.
Annals of internal medicine 1973;79(1):51-8.
1973: Brown W V; Greten H
Type I hyperlipoproteinaemia.
Clinics in endocrinology and metabolism 1973;2(1):73-80.
1972: Gotto A M; Brown W V; Levy R I; Birnbaumer M E; Fredrickson D S
Evidence for the identity of the major apoprotein in low density and very low density lipoproteins in normal subjects and patients with familial hyperlipoproteinemia.
The Journal of clinical investigation 1972;51(6):1486-94.
1972: Brown W V; Baginsky M L
Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein.
Biochemical and biophysical research communications 1972;46(2):375-82.
1972: Brown W V
Some functional aspects of the plasma apolipoproteins.
Verhandlungen der Deutschen Gesellschaft für Innere Medizin 1972;78():1292.
1971: LaRosa J C; Levy R I; Brown W V; Fredrickson D S
Changes in high-density lipoprotein protein composition after heparin-induced lipolysis.
The American journal of physiology 1971;220(3):785-91.
1970: Brown W V; Levy R I; Fredrickson D S
Further characterization of apolipoproteins from the human plasma very low density lipoproteins.
The Journal of biological chemistry 1970;245(24):6588-94.
1970: Bersot T P; Brown W V; Levy R I; Windmueller H G; Fredrickson D S; LeQuire V S
Further characterization of the apolipoproteins of rat plasma lipoproteins.
Biochemistry 1970;9(17):3427-33.
1970: Mahley R W; Bersot T P; LeQuire V S; Levy R I; Windmueller H G; Brown W V
Identity of very low density lipoprotein apoproteins of plasma and liver Golgi apparatus.
Science (New York, N.Y.) 1970;168(929):380-2.
1970: Brown W V; Levy R I; Fredrickson D S
Further separation of the apoproteins of the human plasma very low density lipoproteins.
Biochimica et biophysica acta 1970;200(3):573-5.
1969: Brown W V; Levy R I; Fredrickson D S
Studies of the proteins in human plasma very low density lipoproteins.
The Journal of biological chemistry 1969;244(20):5687-94.
1969: Glueck C J; Brown W V; Greten H; Levy R I; Fredrickson D S
Treatment of hypertriglyceridaemia.
Lancet 1969;2(7625):852.
1969: Glueck C J; Brown W V; Levy R I; Greten H; Fredrickson D S
Amelioration of hypertriglyceridaemia by progestational drugs in familial type-V hyperlipoproteinaemia.
Lancet 1969;1(7609):1290-1.
1969: La Rosa J C; Brown W V; Frommer P L; Levy R I
Clofibrate-induced ventricular arrhythmia.
The American journal of cardiology 1969;23(2):266-9.

Sign-in to see more